文献速递消化系统肿瘤

观点与反方观点:是否应为所有胃肠道癌症患者提供通用胚系基因检测?

Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for All GI Cancers?
PubMed 文献 · J Clin Oncol · 2022-06-01

本文以观点与反方观点形式,讨论是否应为所有胃肠道癌症患者提供胚系多基因panel检测。作者指出,多基因panel可及性提高、成本下降及保险覆盖改善,且美国食品药品监督管理局已批准针对特定胚系变异患者的基因型导向治疗;美国国家综合癌症网络指南已推荐对上皮性卵巢癌、外分泌胰腺癌及高级别/转移性前列腺癌所有患者进行胚系检测,不论年龄或家族史。作者同意可能只是时间问题,但强调需权衡获益、风险与局限,以便研究填补空白。

要点

  • 多基因panel检测可及性提高、成本下降及保险覆盖改善,推动胚系检测应用增加。
  • 美国食品药品监督管理局已批准针对BRCA1/BRCA2胚系致病变异患者的聚ADP核糖聚合酶抑制剂等基因型导向治疗。
  • 美国国家综合癌症网络指南已推荐对所有上皮性卵巢癌、外分泌胰腺癌及高级别/转移性前列腺癌患者进行胚系检测,不论年龄或家族史。

核心结论

  • 作者同意可能只是时间问题,胚系多基因panel检测将提供给所有癌症患者;本文强调需权衡该方法的获益、风险与局限,以便研究填补空白,确保遗传医学以改善真实世界患者照护和结局的方式持续实施。

研究设计与样本

  • 本文为观点与反方观点(Point/Counterpoint)文章,讨论是否应为所有胃肠道癌症患者提供胚系多基因panel检测。

主要发现

  • 胚系基因检测在癌症患者中的应用增加,原因包括:单次检测可包含多个癌症易感基因的多基因panel检测可及、检测成本下降及保险覆盖改善、美国食品药品监督管理局批准针对特定癌症及BRCA1/BRCA2胚系致病变异个体的聚ADP核糖聚合酶抑制剂等基因型导向治疗(同源重组修复缺陷通路其他基因可能获益)。
  • 美国国家综合癌症网络指南已推荐对所有上皮性卵巢癌、外分泌胰腺癌及高级别/转移性前列腺癌患者进行胚系基因检测,不论年龄或癌症个人史/家族史。

局限性

  • 本文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Use of germline genetic testing among patients with cancer is increasing because of (1) the availability of multigene panel tests that include multiple cancer susceptibility genes in a single test, (2) decreased costs of these tests and improvements in insurance coverage, and (3) US Food and Drug Administration-approval of genotype-directed therapies such as poly(ADP-ribose) polymerase inhibitors for individuals with certain cancers and pathogenic germline variants in BRCA1 and BRCA2 (with possible benefits with other genes in the homologous repair deficiency pathway). In addition, National Comprehensive Cancer Network guidelines have already endorsed germline genetic testing for all patients with certain cancer types (epithelial ovarian cancer, exocrine pancreatic cancer, and high-grade/metastatic prostate cancer), regardless of age or personal/family history of cancer. Herein, we debate the pros and cons of offering germline multigene panel testing to all patients diagnosed with any GI cancer. The authors agree that it may just be a matter of time before germline multigene panel testing is offered to all patients with cancer; however, this article will highlight some of the benefits, risks, and limitations of this approach so that research can help fill some of the gaps to ensure that genetic medicine continues to be implemented in ways that improve real-world patient care and outcomes.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hampel H, Yurgelun MB. Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for All GI Cancers? J Clin Oncol. 2022. PMID: 35649230. doi:10.1200/JCO.21.02764

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。